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Purpose: This ‘impact pathways’ paper argues that operations and supply chain management (OSCM) 
could help address the worsening drug shortage problem in high-income countries. This significant 
societal problem poses difficult challenges to stakeholders given the complex and dynamic nature of 
drug supply chains. OSCM scholars are well positioned to provide answers, introducing new research 
directions for OSCM in the process. 
Design/methodology/approach: To substantiate this, we carried out a review of stakeholder reports 
from six European countries and the academic literature.  
Findings: There is little academic research and no fundamental agreement among stakeholders about 
causes of shortages. Stakeholders have suggested many government measures, but little evidence 
exists on their comparative cost-effectiveness.  
Originality/value: We discuss three pathways of impactful research on drug shortages to which OSCM 
could contribute: (1) Developing an evidence-based system view of drug shortages; (2) Studying the 
comparative cost-effectiveness of key government interventions; (3) Bringing supply chain risk 
management into the government and economics perspectives and vice versa. Our study provides a 
baseline for future COVID-19-related research on this topic. 
 





An “ongoing and worsening drug shortage crisis” (FDA, 2019, p.5) emerged before COVID-19 in various 
countries and is aggravating (Farmanco, 2020). Consequences include considerable time and effort 
confronting shortages, delays in treatment, suboptimal treatment, and cancellation of care (EAHP, 
2019; FDA, 2019). In the Netherlands the estimated annual total cost is between 45 and 105 million 
euros (MvVWS, 2019a).  
A drug shortage has been defined as a period when demand or projected demand for a drug exceeds 
its supply (FDA, 2019). Using SCRM terminology, we see shortages as arising from events or conditions 
adversely affecting a supply chain (Ho et al., 2015). Following others (e.g., Jia and Zhao, 2017), we 
refer to such events or conditions as causes. Abnormal causes are rare external events, such as 
pandemics. Normal causes occur frequently, typically originating within the supply chain, such as 
fluctuations in demand, production problems, or delays in distribution (Ho et al., 2015; Sodhi and 
Tang, 2012). We use the term interventions for measures taken to decrease the likelihood of adverse 
events and their impact. Interventions resemble SCRM strategies, typically concerned with how 
companies can mitigate risk in their supply chains (Tang, 2006; Roscoe et al., 2020). In contrast, we 
focus on governmental measures that may mitigate the risk of shortages. Government action is 
believed to be crucial here (De Weerdt et al. 2015), and COVID-19 is reinforcing this belief. When 
deciding which government intervention(s) to implement, several questions arise: What are the 
causes? What is their relative importance? How are they interconnected? Which interventions are 
likely to be most effective, and at what cost?  
This impact pathways paper argues that OSCM could help answer these questions. We present an 
agenda for further research, based on a review of the academic literature on drug shortages combined 
with an analysis of secondary data pre-COVID from six European countries.  
Our study focuses on off patent and generic prescription drugs, which represent most drug shortages 
(EAHP, 2019; FDA, 2019) and provides a baseline for future COVID-19-related research on this topic.  
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Both supply chain risk management (SCRM) (Sodhi and Tang, 2012) and resilience (van Hoek, 2021) 
provide useful perspectives, where some see the first as an enabler of the latter. Research on resilient 
medicine supply chains has been very scant (c.f. Lücker and Seifert, 2017; Tucker et al. 2020). We agree 
with Ellis (2020) that risk management in pharmaceutical supply chains should be a “strategically 
imperative exercise that is regularly revisited, not one to dust off when a disruption occurs” (p.8).  
 
2. Stakeholder perceptions of causes and interventions 
We searched websites of stakeholder organizations in Belgium, France, the Netherlands, Norway, 
Sweden, and the United Kingdom for material on drug shortages published between January 1st 2010 
and December 31st 2019 resulting in 134 relevant sources. For each country, two researchers were 
involved in coding and analyzing the data.  Further details are provided in link to online-addendum], 
section A.  
2.1 Claim 1: There is no real agreement among stakeholders about causes of drug shortages  
Firstly, many sources report first-level causes and do not link them to underlying issues. Typically, 
manufacturing problems, and “other supply chain related problems” are listed as key causes, with no 
mention of possible underlying economic causes (NoMA, 2019), for example price, tendering, and 
reimbursement policies. Such policies can affect supply bases, inventories, production quality and 
capacity, and lead times, but there is little evidence. It has been shown in other sectors that pressure 
on prices results in outsourcing manufacturing to low-cost economies, making supply chains more 
vulnerable to disruptions (van Hoek, 2020). 
Secondly, though dozens of causes can be identified, sources typically report a small subset which 
differs substantially between countries.  For example, Belgian and UK sources make no reference to 
impacts of prices and margins on inventories, and only the Netherlands and France report effects of 
quality issues. Sources also differ within countries. Norwegian pharmaceutical manufacturers list 
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manufacturing problems and demand increases as key causes (LMI, 2018) whereas the Directorate of 
Health emphasizes long lead times, just-in-time inventory management, hoarding, and market size 
(HDir, 2019). Similarly, the UK’s National Pharmacy Association (2020) highlights quota systems 
imposed by manufacturers as an important cause, while manufacturers point to pharmacies and 
wholesalers exporting medicines intended for the UK (ABPI, 2019).  
2.2 Claim 2: Many suggested interventions but little evidence or knowledge of what works 
Most shortages are managed reactively instead of proactively, focusing “more on decreasing the 
effects of shortages or dealing with their consequences than on the underlying causes” (MvVWS, 
2019, p.19). There is vast diversity among additional interventions considered, many resembling 
SCRM-strategies, such as better information sharing and adding redundancy through emergency 
stock. Interventions to enhance the flexibility (Tang, 2006) are also frequently suggested, such as 
awarding contracts to multiple suppliers to counter monopoly formation and ensure a “supply base 
that can be drawn upon in the event of a failure” (SFR 2018, p.98). Stakeholders also consider 
numerous interventions not easily categorizable in SCRM frameworks such as substituting medicines 
that are out of stock and rationing and allocating scarce supplies. Widely recommended is bringing 
production back to Europe. This resembles the make or buy SCRM strategy (Tang, 2006), but uses 
government incentives as opposed to in-house vs. outsourcing decisions by manufacturers.  
However, stakeholders provide little evidence on cost effectiveness. For example, the Dutch 
government analyzed the effects of 27 interventions and concluded they were mostly difficult to 
assess or unknown (MvVWS, 2019). We found no analysis of which interventions are more cost- 






3. What research has contributed so far 
We identified 506 articles in our scientific literature review and read 79 in depth, and classified each 
article in terms of context, purpose, type of evidence provided, intervention analysis, cause analysis 
and research methodology. Three of the authors were involved in coding to secure inter-rater 
reliability. See [link to online-addendum], section B for details of search terms and inclusion criteria.  
3.1 Claim 1: OSCM has so far played a marginal role in studying the drug shortage problem 
We identified only ten articles on drug shortages in OSCM-related journals (Azghandi et al., 2018; 
Chang et al. 2019; Dai et al., 2016; Jia and Zhao 2017; Kochan et al., 2018; Liao et al., 2015; Lu and Shi, 
2019; Shiau, 2019; Tucker et al.; 2020; Zadeh et al., 2014). The remaining identified articles make little 
use of models, tools, or concepts from our field. 
3.2 Claim 2: More research presenting a comprehensive view on shortage causes is necessary 
Scholars agree that recent increases in drug shortages are driven by several trends (De Weerdt et al., 
2015; Heiskanen et al., 2017; Pauwels et al., 2014; Tucker et al., 2020; Yurukoglu et al., 2017). 
However, most papers that express a view on the causes present either no new evidence or evidence 
relating to first level causes only. Papers aiming to assess the causes comprehensively use mainly 
expert opinion and mechanism-based reasoning, regarded by health scientists as relatively weak 
evidence (Van de Klundert, 2016). Studies examining causal interrelations are particularly scarce.  
Like stakeholder reports, academic papers report primarily on first-level causes. Indeed, Pauwels et 
al. (2014) conclude that “no efforts [have yet been made] to unveil the root causes” (p.7). This may 
be the consequence of eliciting stakeholder views on causes of specific shortages, directly or via 
reporting platforms. 
Heiskanen et al. (2017) and Pauwels et al. (2015) do reveal several underlying causes but provide no 
new evidence on how these factors could be interrelated or impacted further upstream. Woodcock 
and Wosinska (2013) explore such interrelationships with economic theory to argue that disincentives 
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in the pharmaceutical market can worsen shortages. De Weerdt et al. (2015) use inference from 
economic mechanisms and stakeholder reports to indicate how European and national laws might 
affect drug shortages. We found only three studies that apply econometric modeling to study causality 
between shortage and pricing. Yurukoglu et al. (2017) showed that shortages rose for drugs whose 
prices decreased most significantly. Ridley et al. (2016) revealed that a higher price is associated with 
a lower likelihood of shortage. Parsons et al. (2016) show that having maximum four suppliers makes 
shortages more than twice as likely to occur compared to having five or more suppliers.  
3.3 Claim 3: More work is needed to assess holistically the cost-effectiveness of suggested 
government interventions  
To assist governmental decision-making, there is a need for research that 1) examines proposed 
interventions for which cost-effectiveness is unclear, 2) provides strong evidence of comparative cost-
effectiveness, and 3) assesses the direct and indirect implications for all relevant stakeholders. For 
example, to assess the impact of changes in procurement one should consider effects on market 
attractiveness and the number of suppliers. Only 18 studies provide any evidence on implementation 
costs and/or effectiveness of proposed interventions. All papers that present empirical evidence (7 of 
the 18) comprise case studies of a specific stakeholder’s response to a shortage. Similarly, more than 
half of the papers that present evidence from modeling and numerical simulation consider a single 
stakeholder and a single intervention (cf. Zadeh et al., 2014). Reliance on such local optimization can 
miss implications for upstream and downstream parts of the supply chain (Settanni et al., 2017).  Two 
modelling/simulation papers (Azghandi et al., 2018; Kochan et al., 2018) account for multiple 
stakeholders but do not consider the government. Dai et al. (2016) study how the US government 
could mitigate shortages of an influenza vaccine through incentivizing a manufacturer to initiate early 
production, and Jensen et al. (2015) investigate how the US Food and Drug Administration (FDA) 
collaborated with manufacturers to take last-minute risk-mitigation actions. Half the articles cover 
reactive interventions, like rationing, allocation, or substitution, and last-minute risk mitigation. 
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Accordingly, there is great potential for research on proactive interventions that governments could 
consider.  
We identified two papers that illustrate urgently needed research taking a systems perspective 
(capturing multiple stakeholders, causes beyond first-order ones, interdependencies of causes). Jia 
and Zhao (2017) model the impact of increasing prices and failure-to-supply penalties on 
manufacturers’ inventory and capacity decisions, and the subsequent effect of those decisions on 
shortages. Tucker et al. (2020) use a multi-stage stochastic model to simulate how government 
interventions affect a manufacturer’s decisions on supply chain design and inventories and estimate 
how this affects societal costs and shortages.  
 
4. Pathways for future research 
4.1 Pathway item 1: Develop an evidence-based system view  
Sections 2.1 and 3.2 describe limited evidence on the causes of shortages, their relative importance, 
and how they interrelate. With the notable exception of a study on the link between the number of 
suppliers and shortages (Parsons et al., 2016), we found no studies that quantify the cause-and-effect 
relationships linking causes related to pricing, tendering and reimbursement to shortages. That means 
a serious risk of stakeholders and academics missing important dynamics and knock-on effects. For 
example, we did not identify any modeling studies that capture how interventions impact the number 
of suppliers, even though it is widely believed that they may. Furthermore, research on how 
interventions can backfire is needed. For example, joint tendering is claimed to increase appeal for 
their markets (Eversana, 2020), while France argues that it could decrease the number of suppliers 
and increase vulnerability (SRF, 2018).  
We therefore advocate further research that can 1) establish sound evidence on understudied cause 
and effect relationships and 2) combine it with evidence from existing literature to establish a system 
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view of the problem. We need research that builds the whole from the parts. OSCM expertise in 
studying and modeling complex dynamic systems will be paramount here, combined with expertise 
from the health sciences and economics. We see a large potential role for system dynamics modeling 
and econometric models that assess causality. These methods would be very suitable for studying 
links between prices and other underlying causes and manufacturing disruptions, inventories, parallel 
trade, lead times, and the number of manufacturers. Building on the leading studies identified in this 
review, such research could complement publicly available data sets, with direct engagement with 
relevant stakeholders.  
4.2 Pathway item 2: Studying the comparative cost-effectiveness of key government 
interventions 
Section 3.3 highlights the paucity of evidence on the cost-effectiveness of proposed governmental 
interventions. We therefore call upon OSCM researchers to develop and parametrize models for this: 
Establishing strategic stocks. Legal requirements for inventory levels (or lead times) and 
corresponding failure-to-supply penalties have been considered in several countries. Countries 
struggle to decide how high such inventory levels should be, where the inventory should be kept, 
whether and how to differentiate by medicine, how to finance, and how to enforce. The challenge of 
specifying legal requirements differs from traditional inventory management, notably that a policy 
should be expressed in relatively simple language – e.g., keep a safety stock of 𝑥 months of demand 
for medicines with characteristics 𝑦 and 𝑧.  Furthermore, evaluations should take into consideration 
that such interventions can change the “future state” of the system. For example, there are concerns 
that increasing penalties carries the risk that manufacturers with small revenues or low prices will 
withdraw from the market. OSCM scholars have the potential to inform this debate by developing 
models to optimize market-wide inventory policies and failure-to-supply penalties and account for 
market withdrawals. Such models can be parametrized using publicly available data on drug demand, 
prices, market authorization holders, and shortages.  
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Reshoring of drug manufacturing. The OSCM community possesses much expertise that could inform 
debates around reshoring of drug manufacturing. COVID-19 has led to many calls for action and the 
comparative cost-effectiveness of possible strategies is hugely interesting. Reshoring will certainly 
increase costs (France24, 2020), and it is questionable to what extent it will resolve problems, partly 
because upstream supply chains (e.g., for Active Pharmaceutical Ingredients) may remain global. 
There is a clear need for more OSCM research on the total system cost-effectiveness of reshoring, how 
it differs for specific drugs and countries, how it depends on other countries’ reshoring decisions, and 
how it compares to the effects and costs of other interventions.  
Revising pricing, tendering, and reimbursement practices. Interventions that tackle economic causes 
– pricing, tendering, and reimbursement practices – are a third important research area. Since tackling 
these practices is perceived to conflict with the objective of maximizing affordability, a delicate 
balance needs to be struck (cf. Musazzi et al., 2020). OSCM expertise on game theoretic modeling and 
mechanism design, parametrized using data on shortages, prices, numbers of market authorization 
holders, and expertise on procurement practices could help address this question.  
Future research in this area would also benefit from a behavioral OSCM perspective (Bendoly et al., 
2010) to examine how cognitive and psychological factors impact contractual relationships in drug 
supply chains. For instance, framing bias is relevant to consider when designing tenders and contracts 
(Selviaridis and van der Valk, 2019), e.g. whether switching from a predominant ‘prevention’ contract 
framing (emphasizing control and penalties to suppliers) to a ‘promotion’ (stressing supplier rewards) 
could help instigate collaboration and flexibility in supplier relationships. Studying how perceptions of 
fairness (e.g. regarding pricing), trust and power influence contractual negotiations would also be a 
fruitful avenue for further research.             
4.3 Pathway item 3: Bringing the government perspective and economics into supply chain 
risk management  
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Many interventions suggested by stakeholders could be classified using common SCRM frameworks. 
We nevertheless see two fundamental differences that can push the frontiers of SCRM research. First, 
interventions could be addressed from a government perspective, and thus complement existing 
SCRM studies. Governments and their policies have a critical role in mitigating supply chain disruptions 
(Scholten et al. 2020). As they are rarely directly engaged in the production and distribution of 
medicines, interventions are usually indirect. COVID-19 shows that governments are increasingly 
intervening to avoid or minimize shortages. For example, they have traditionally not been involved in 
decisions on production locations, but some plan to influence them through economic incentives. 
Similarly, most governments have not stocked medicines but are now planning to influence stocks 
kept by firms by introducing regulations and fines. Studying inventory management and facility 
location from a company perspective can hence be fundamentally different from studying stockpiling 
and production reshoring resulting from government regulations. The same applies to procurement, 
distribution, quality and capacity management, and so on. Sound analyses of government policies’ 
effect on supply chains have received limited attention (Scholten et al. 2020). Second, although 
maintaining a diverse supply base is recognized as a SCRM strategy, supply base decisions have 
typically been made by existing supply chain members, i.e. the buying organization. Our context 
highlights the need to understand how supply base design is impacted by other actors’ decisions to 
enter or exit a market.  
It would be very helpful to have models that capture these decisions. Several general supply chain 
economics models are available (Corbett and Karmarkar, 2001; Korpeoglu et al., 2020), but they 
include some assumptions that do not hold for medicine supply chains. They also analyze outcome 
variables other than availability, or study interventions and decision variables that may not apply. We 
therefore advocate that researchers should develop models that capture 1) relevant interventions, 2) 
their impact on entry/exit decisions, 3) the direct and indirect implications for supply chain risk. 
Collaboration between economists and OSCM researchers is essential here. 




Figure 1: Visualizing the suggested pathways 
4.4 Final remarks 
We have seen many calls for OSCM scholars to increase the relevance of their research (Van 
Wassenhove, 2019) and undertake studies that are practice-based and responsible (Lee and Tang, 
2018), contributing towards more sustainable and resilient supply chains (Sarkis, 2021), but 
accounting for difficult trade-offs (Matos et al. 2020). The continuing problem of drug shortages 
demands that the OSCM community gets more involved and provides us with a great opportunity: (1) 
the problem has substantial patient and economic impacts; (2) it poses complex questions for 
stakeholders to which there is no obvious answer; (3) OSCM scholars are well positioned to address 
these questions; and (4) the problem introduces fundamentally new research directions for OSCM and 
pushes the frontiers of our discipline. COVID-19 has amply demonstrated why such work is urgently 
needed. The pandemic has substantially worsened the situation, not only for COVID-related medicines 
and vaccines, but also in terms of strong knock-on effects on regular drug supply, particularly in low- 
and middle-income countries. More resilient and sustainable drug supply chains will provide better 
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Appendix A: Review and analysis of the grey literature  
We conducted an analysis of publicly available secondary data (including policy reports, governmental 
communications, and press articles) on drug shortages in six European countries: Belgium, France, the 
Netherlands, Norway, Sweden, and the United Kingdom. We selected these six because they are 
representative of the high-income country settings we are focusing on. Our research group consists 
of researchers who speak different languages and can read public reports published in these countries. 
For each country, we searched for drug shortages-related issues, causes of shortages and (ongoing) 
interventions pursued to tackle these shortages following four key steps. First, we consulted the latest 
risk analysis documents published by ministries/governmental agencies, or other equivalent 
publications to get an overview of the drug shortages problem, and to identify additional sources 
referred to in these documents (through snowballing). Second, we researched the website of the 
Ministry of Health (or equivalent) in each of the six countries. This step also helped to identify 
additional key stakeholders: public health agencies, healthcare providers, manufacturers, wholesalers 
and distributors, and patient representative organisations. Third, and based also on inputs from the 
two previous steps, we researched in detail the websites of all key stakeholders in each country. 
Fourth, we complemented these results by searching online for any press articles focusing on drug 
shortages. The stakeholders and key data sources per country we studied are shown in Table 1.  
Table 1: Stakeholders and key data sources per country for the grey literature analysis 
Country 
Stakeholder 
Norway: search for 
“legemiddelmangel”; 
“vaksinemangel” on website of 
the stakeholders  
Sweden search for “brist 
läkemedel” on website of the 
stakeholders  
Netherlands search for 
“geneesmiddelen tekort” on 
website of the stakeholders  
Agency for 
Risk Analysis 
The Norwegian Directorate for 
Civil Protection - DSB 2018. 
https://www.dsb.no/ 14 hits; 0 
hits 
Swedish Civil Contingencies 
Agency - MSB 2013; 2017; 2018 
https://www.msb.se/ 244 hits  
No such thing in NL 
Ministry of 
Health 
Ministry of Health and Care 
Services - HoD 2018; Meld. 
St.28. 2014–2015; Meld. St.10. 
22016-2017; Meld. St.34. 2015-
2016; IS-2635 2017. 
https://www.regjeringen.no/no/de
p/hod/id421/ : 27 hits; 2 hits;  
Ministry of Health and Social 
Affairs - SOU 2013; 2017; 
Regjeringskansliet 2015; 2016; 










Norwegian Directorate of Health 
- HDir 2018a; b. 
https://helsedirektoratet.no/: 14 
hits; 0 hits 
Socialstyrelsen 2016a; b 
http://www.socialstyrelsen.se/ 
692 hits  





Norwegian Institute of Public 
Health – FHI Johansen et al. 
2017. 
https://www.fhi.no/  0 hits; 1 hit;  
Public Health Agency of Sweden 
– FHM 2017. 
https://www.folkhalsomyndighet
en.se/ 331 hits 
Public health institute: 
https://www.rivm.nl 585 hits  
Medicines 
Agency 
Norwegian Medicines Agency – 
LMV; Harborg 2017.  
https://legemiddelverket.no/ 367 
hits; 0 hits 
Swedish Medical Products 
Agency – LMV 2017; 2018. 
https://lakemedelsverket.se/ 889 
hits 
Assessment body for drugs: 
https://www.cbg-meb.nl/ 285 hits 
Hospital 
Sykehusinnkjøp – HF 2018. 
https://sykehusinnkjop.no/ 5 hits; 
0 hits 
Landstingen - SKL 2014. 






Association of the 
Pharmaceutical Industry in 
Norway - LMI 2016. 
https://www.lmi.no/ 44 hits; 0 
hits 
Swedish Association of the 
Pharmaceutical Industry – LIF 
2018. 
https://www.lif.se/ 15 hits 
Generics pharma sector: 
http://www.bogin.nl/ scanned all 
news articles. association for new 
drugs: 
https://www.vereniginginnovatie
vegeneesmiddelen.nl/  208hits  
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Wholesaler Norwegian Pharmacy 
Association – NPA 2017. 
https://www.apotek.no/ 22 hits; 0 
hits  









ng.se/ 41 hits  
Pharmacists association: 











rt&Search=  28 hits  
Other 
National Center for Medicine 
Shortages and Preparedness in 













e/  (no search function) 
https://www.apotekarsocieteten.s
e/ 4 hits 
Statistics body for pharma sector: 
https://www.sfk.nl/  137 hits 
Insurance companies association: 
https://www.zn.nl 54 hits 




Website monitoring body for 
drug wholesales: 
https://www3.sfk.nl/tekorten/  
Website statistics on Dutch 
pharmacy: https://www.sfk.nl/  
    
Country 
Stakeholder 
United Kingdom – search for 
“medicine shortages” and 
“vaccines shortages” on the 
website of the relevant 
stakeholders; also search for 
“Brexit and medicines supply”, 
“Brexit and vaccines supply”.  
Belgium – search strategy: 
search for “geneesmiddelen 
tekort” on website of the 
stakeholders 
France – search strategy: search 
for “penurie medicaments” 
Agency for Risk 
Analysis 
The Civil Contingencies 
Secretariat (part of the UK 
Cabinet Office) website: 
https://www.gov.uk/government/
emergency-preparation-reponse-
and-recovery - 8 hits 
Not found for Belgium 
Agence Nationale de Securite du 
Medicament et des produits de 








health-and-social-care - 724 hits   












Medicine and Healthcare 





agency - 245 hits  
National Institute for Health and 
Care Excellence website: 
https://www.nice.org.uk/ - 0 hits 










Public Health England website: 
https://www.gov.uk/government/
organisations/public-health-
england - 274 hits  
NHS England website: 
https://www.england.nhs.uk/  - 
216 hits  





=Zoeken 40 hits 
Public Health France: 
http://www.santepubliquefrance.f
r/  INVS: 31 hits; INPES: 
29 hits;  
Medicines 
Agency 
Medicine and Healthcare 
Products Regulatory Agency 
website: 
https://www.gov.uk/government/
Agentschap Zorg en Gezondheid 
https://www.zorg-en-
gezondheid.be/ 2 hits  
Agence Generale des 
Equipements et Produits de Sante  





agency - 244 hits (same hits as 
above, see “Health regulator” 
category)  
(NHS) Specialist Pharmacy 






org.uk/ - 0 hits  
Belgische Vereniging der 
Ziekenhuizen: 
http://www.hospitals.be  
Federation Hospitaliere de France 
https://www.fhf.fr/gestion-
hospitaliere/association-
hopital.html 804 hits 
Manufacturer 
Association of the British 
Pharmaceutical Industry website: 
https://www.abpi.org.uk/ - 53 hits 
UK Bio Industry Association 
website: 
https://www.bioindustry.org/ - 90 
hits 
Algemene Vereniging van de 
Geneesmiddelenindustrie: 
https://pharma.be/nl/ 4 hits   




Bachi: http://www.bachi.be/nl/  0 
hits  
Les Entreprises du Medicament  






are - 17 hits 
Algemene Vereniging van de 
Geneesmiddelenindustrie: 
https://pharma.be/nl/ 4 hits  
 
Retailer 
The Pharmaceutical Services 
Negotiating Committee website: 
https://psnc.org.uk/dispensing-
supply/supply-chain/ - 52 hits  




Company Chemists’ Association 
website: 
https://www.thecca.org.uk/ - 3 
hits 
Association of Independent 




https://www.apb.be/ 15 hits  
Koninklijke Apothekers 
Vereniging Antwerpen (KAVA) 
https://www.kava.be/ (no search 
function) 
Belgische/Vlaamse Vereniging 
van Ziekenhuis Apothekers 
(BVZA or VZA): 
http://www.vza.be/nl/default/657
9/BVZA-ABPH.aspx 24 hits  
Hospital Pharmacists of Belgium 
(terrible website): 
http://www.hospitalpharmacistbel
gium.eu/ (no search function) 




The Patients Association website: 
https://www.patients-
association.org.uk/ - 9 hits  
Vlaams patientenplatform 
http://vlaamspatientenplatform.be
/ 13 hits  
France Assos Sante 
http://www.france-assos-
sante.org/ 1 hit 
Other 
Royal Pharmaceutical Society 
website: 
https://www.rpharms.com/ - 64 
hits  
British Medical Association 
website: 
https://www.bma.org.uk/ - 354 
hits 
Dispensing Doctors’ Association 
website: 
https://www.dispensingdoctor.or
g/  - 26 hits 
Department for Exiting the 
European Union website: 
https://www.gov.uk/government/
organisations/department-for-
exiting-the-european-union - 23 
hits 
Repertorium van het Belgisch 
Centrum voor Farmaceutische 
Informatie (BCFI): 
http://www.bcfi.be/nl/start 10 hits  
 







Through the process described above we identified a total of 133 documents that the key stakeholders 
produced across the six countries. The full list of the documents we analysed is provided at the end of 
this appendix. It is noted that we carried out a second wave of data collection in August 2020 to ensure 
that we had covered all relevant documents up until the end of December 2019. We intentionally 
excluded 2020 documents from our sample because our focus was on drug shortages pre-COVID-19.  
We downloaded all the documents and stored them into a common database (Dropbox folder) that 
we created for this purpose. We fully read the documents and analysed their contents in an excel 
sheet based on a simple coding framework we designed for analytical purposes. This framework 
included the following classification schemes: observed shortages; causes of shortages; and 
interventions to address shortages. Table 2 shows the framework and related classification schemes. 
Table 2: Scheme for classification of grey literature on drug shortages 
Classification 
scheme 
Related categories Initial Scientific Sources 
Demand Related Causes 




Little demand flexibility 
Limited information on demand evolution 
Changing Demand Pattern 
Epidemic, Natural disaster, War/terrorism, Fires, Political 
instability, Economic downturns, External legal issues, 




Lack of raw materials 
Manufacturer quotas 
Few manufacturers - specify root causes 
Inflexible manufacturing capacity 
 Ho, W., Zheng, T., Yildiz, H. 
and Talluri, S. 2015. Supply 
chain risk management: a 
literature review. International 
Journal of Production 
Research, 54(16), 5031–5069. 
 
Supply Related Causes 
of Shortage – normal 
and abnormal 
Entry barriers 
Mergers and acquisitions 
Decisions based on product and market attractiveness 
Local production 
Market strategies 
Complex and long production processes and quality 
controls 
Tight production planning 
Geographic concentration 
Counterfeits demanding recalls 
Lack of raw materials 
Deliberate low inventories 
Production problems 
Limited information on current and future supply 
capacity and risk of shortage 
Small customer  
Information system failures 
Deliberate low inventories 
Few wholesalers 
Lack of SC transparency 
Cross-border drug trade 
Information system failures 
Deliberate low inventories 
Epidemic, Natural disaster, War/terrorism, Fires, Political 
instability, Economic downturns, External legal issues, 
Regional instability, Government regulations, Social and 
cultural grievances, Brexit 
Ho, W., Zheng, T., Yildiz, H. 
and Talluri, S. 2015. Supply 
chain risk management: a 
literature review. International 
Journal of Production 
Research, 54(16), 5031–5069. 
 
Effects of shortages  Effects on patients: does not discuss /analyse (N); simply 
discusses (D); analyses primary data (P); analyses 





Economic /financial effects: does not discuss /analyse 
(N); simply discusses (D); analyses primary data (P); 
analyses secondary data (S)  
Market interventions Economic supply incentives 
Limit parallel trade 
Flexible supply termination/ smoothen number of players 
in the market 
Law enforcement for: notification of halting/pausing 
supply 
Law enforcement: Effort obligation for sufficient 
inventories 
Tang, C.S. (2006a), “Robust 
Strategies for mitigating supply 
chain disruptions”, International 
Journal of Logistics: Research 
and Applications, Vol. 9 No. 1, 
pp. 33–45. 
Medical interventions Silent product rollover ('Prescribe' a different product due 
to shortages of the original) 
Allocation rules/ rationing (In case of shortages, no rules 
on which patients should be prioritized) 
Flexible quality standards/product characteristics 
Tang, C.S. (2006a), “Robust 
Strategies for mitigating supply 
chain disruptions”, International 
Journal of Logistics: Research 






Flexible supply base 
Supply contracts 
Flexible manufacturing process 
Flexible transport 




Dynamic assortment planning 
Jahre, M. 2017. Supply Chain 
Strategies in Humanitarian 
Logistics: A Review of how 
Actors Mitigate Supply Chain 
Risks. Journal of Humanitarian 
Logistics and Supply Chain 
Management, 7(2), 82-101.;  
Lavastre, O., Gunasekaran, A. 
and Spalanzi, A. (2014), “Effect 
of firm characteristics, supplier 
relationships and techniques 
used on supply chain risk 
management (SCRM): an 
empirical investigation on 
French industrial firms”, 
International Journal of 
Production Research, Vol. 52 
No. 11, pp. 3381–3403. 
Tang, C.S. (2006b), 
“Perspectives in supply chain 
risk management”, International 
Journal of Production 
Economics, Vol. 103, pp. 451–
488 
Chopra, S. and Sodhi, M.S. 
(2004), “Managing Risk to 
Avoid Supply-Chain 
Breakdown”, MIT Sloan 
Management Review, Fall 
2004, pp. 53 61;  
Manuj, I. and Mentzer, J.T. 
(2008), “Global supply chain 
risk management strategies”, 
International Journal of 
Physical Distribution and 
Logistics management, Vol. 38 
No. 3, pp. 192–223. 
 
We inductively coded observed shortages in terms of medicines and /or vaccines in short supply, 
and any associated details. Regarding causes of shortages, our coding framework drew a distinction 
between demand- and supply-related causes, and between normal and abnormal causes following 
prior research on supply chain risk management (Ho et al., 2015). Based on these classification 
schemes, observed causes of shortages were coded into one the four categories: “demand-related, 
normal cause” (e.g. changing demand patterns), demand-oriented, abnormal cause” (e.g. epidemic 
outbreak), “supply-related, normal cause” (e.g. single sourcing and limited manufacturing capacity), 
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and “supply-related, abnormal cause” (e.g. import /export bans). Regarding interventions, our 
coding scheme identified three key categories based on Tang (2006), Sodhi and Tang (2012), and Ho 
et al. (2015): “market” (e.g. economic supply incentives), “supply chain” (e.g. flexible supply base), 
and “medical” interventions (e.g. rationing or allocation rules).  
Coding and analysis of the country-specific reports was conducted by a team of twelve researchers 
(including four of the authors). For each country, two researchers were assigned to code the 
secondary data to ensure bias-free analysis and assessment of the document sources. Specifically, 
for each country we selected a small sample of documents that both researchers coded, and then 
compared our within-country coding. All coding disagreements were discussed and eventually 
adjudicated. In addition, during the data coding process, we held lengthy discussions, and made 
iterations, to ensure a standardized approach to our coding across the six countries. All these steps 
increased our confidence regarding the reliability of our coding and analysis. Further details 
regarding the steps taken to ensure inter-coder reliability are available upon request.  
List of documents we analysed in the six countries 
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Appendix B: Review and analysis of the academic literature  
To ensure rigour and replicability of our survey of the academic literature, we followed a systematic 
literature review approach (Tranfield, Denyer and Smart, 2003). The process commenced with 
reviewing key articles on shortages of medicines and vaccines in pharmaceutical supply chains. 
Specifically, we selected thirteen articles that we deemed important (e.g. Dobrzykowski et al., 2014; 
Duijzer et al., 2018; Jia and Zhao, 2017; Mamani et al., 2013; Pauwells et al. 2014; Settanni et al., 2017;) 
based on our expert judgement and familiarity with key authorities in this research field. This research 
scoping exercise informed our subsequent definition of literature search terms and the design of a 
classification framework we used to code and analyse the research articles we reviewed.  
The initial scoping study also confirmed our expectation that the topic of drug shortages spans 
across disciplines, notably health and life sciences, biomedical sciences, and operations and supply 
chain management (OSCM). Accordingly, we decided to devise a rather broad literature search 
strategy relying on the Web of Science (WoS) database and the PubMed database, which is maintained 
by the US National Library of Medicine at the National Institutes of Health. The WoS database was 
selected because it is broad in its coverage of peer-reviewed journals across fields of study, including 
OSCM, operations research and healthcare services. Specifically, as part of our preparatory work we 
confirmed that the WoS database includes all major OSCM journals, broadly define as journals 
classified by WoS as Operations Research and Management Sciences, Mathematics (and related 
categories such as Mathematics and Computational Biology), or Engineering (and related categories 
such as Computer Science and Engineering).The PubMed database was chosen as a complementary 
source of scientific literature given its emphasis on health science- and medicine science-related 
outlets. An additional reason for using both databases was our intention to identify any similarities 
and differences between health sciences outlets and OSCM journals with respect to their relative focus 
on the shortages topic, and the approaches they use to study drug shortages.  
We conducted a keyword-based search in both databases. We jointly defined our search terms 
considering also the findings of our initial scoping study. We used the following search terms in 
combination: “medicin* shortage*”, “drug* shortage*”, “medicinal* shortage*”, and vaccine* 
shortage*. We restricted our search to peer-reviewed articles (i.e., we excluded conference 
proceedings, books, and other document types) written in English. We also decided to restrict our 
literature review to articles published from January 2009 to December 2019 (inclusive). We opted for 
setting 2009 as our starting year given that the drug shortages topic attracted increasing interest in 
practitioner and academic circles alike during the 2010s, as also reflected by the organisation of the 
First International Summit on Medicines Shortages in June 2013, which was hosted by the 
International Pharmaceutical Federation.  
This first search step produced 397 hits for the WoS database, and 256 hits for the PubMed. 
After merging the two searches and removing duplicates, we arrived at a set of 514 articles. Next, two 
of the authors read the abstracts of all 514 articles to evaluate their relevance, and to decide whether 
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they should be included in our subsequent detailed analysis. During this step, we excluded many 
articles because these addressed none of the following aspects of interest: shortages observed, causes 
of shortages, effects of shortages, interventions to tackle shortages, or impact of interventions. This 
assessment and elimination process resulted in a set of 83 articles that qualified for our detailed 
analysis and classification. We downloaded and stored all these articles into a scientific literature 
database we jointly maintain. We also noted the publication details of each article: authors, year, title, 
and journal.  
Next, we developed a comprehensive file for data extraction (Tranfield et al., 2003) based on 
a spreadsheet which we used to classify the chosen articles. Table 3 presents all the classification 
schemes we developed, and their respective categories. For our literature analysis we used the 
following classification schemes: shortages studied, country in focus, medicines/vaccines in focus, 
type of situation (normal vs. extreme), causes of shortages, effects of shortages on patients and 
healthcare costs, types of interventions to address shortages, impact of interventions, and explicit 
reference of study to OSCM scholarship. For the classification of observed shortages, causes and 
impacts of shortages, and interventions to address shortages, we were interested to know whether 
the articles simply discussed those, or provided analysis based on primary or /and secondary data. 
Regarding the classification according to whether an article studies causes of shortages (yes /no), we 
defined the content of additional related schemes in terms of number of causes identified (low=1-5; 
medium=6-15; high=16-plus), the level of analysis (first-level vs. root-cause) and (non)linearity of 
analysis (linear vs. causal loop analysis).  
With respect to interventions, we defined three types (medical, supply chain, and market 
interventions) based on our early consultation of key studies and our expert knowledge. In addition, 
we wanted to know whether the articles we reviewed provided any evidence (either empirical or 
modelling-based; or both) on the impact of interventions. Amongst other categories, we defined 
interventions in terms of scope (one vs. multiple interventions), their proactivity extent (reactive; 
proactive; both), and any impact metric used to quantify the effects of an intervention. In total, we 
used 20 classification fields to code the data.  
 
Table 3: Schemes for classification of academic literature on drug shortages 
Classification scheme Related categories 
Shortages observed  Does not present data on shortages (N); Presents /analyses primary data (P); Presents 
/analyses secondary data (S) 
Country /countries in focus Open-ended categories (inductively derived) 
Medicines /vaccines studied Open-ended categories (inductively derived) 
Type of situation  Normal situations vs extreme situations 
Causes of shortages Does not discuss /analyse shortages (N); Discusses causes (D); analyses primary data 
on causes (P); analyses secondary data (S) 
Number of causes (low, medium, high)  
Systematic root-cause analysis (yes /no) 
Linear cause analysis vs. causal loop analysis  
Effects of shortages  Effects on patients: does not discuss /analyse (N); simply discusses (D); analyses 
primary data (P); analyses secondary data (S)  
Economic /financial effects: does not discuss /analyse (N); simply discusses (D); 
analyses primary data (P); analyses secondary data (S)  
Interventions to tackle 
shortages 
Medical interventions: does not discuss /analyse (N); simply discusses (D); analyses 
primary data (P); analyses secondary data (S)  
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Supply chain interventions: does not discuss /analyse (N); simply discusses (D); 
analyses primary data (P); analyses secondary data (S)  
Market interventions: does not discuss /analyse (N); simply discusses (D); analyses 
primary data (P); analyses secondary data (S)  
Impact of interventions Evidence on impact of intervention: empirical; modelling; both; None (if the study does 
not provide evidence of impact) 
Reactive interventions; proactive interventions; both; None (if no impact evidence 
provided)  
One intervention vs. multiple interventions; None (if no impact evidence provided)  
Research method (if empirical evidence provided): open-ended categories, derived 
inductively 
Impact metric used (if impact evidence provided): open-ended categories, derived 
inductively  
Optimisation /scenario analysis (if impact evidence provided): yes /no 
Reference to OSCM studies  Uses concepts /approaches from OSCM literature: yes /no 
 
Three of the authors were involved in reading, evaluating, and classifying the set of 83 articles we 
included in our detailed review. To ensure high level of interrater reliability, we initially identified a 
common subset of 13 articles (15% of the total number of studies) that each author assessed 
independently. The three authors then met to compare and discuss their respective classifications and 
coding. This step resulted in an interrater agreement of 91% - out of 260 classification fields in total 
(20 fields x13 articles), there were 24 disagreements in our coding. We discussed all disagreements  
to identify possible sources of misinterpretation regarding the definition and application of the 
classification schemes. All disagreements were subsequently adjudicated.  
Based on such discussions and given the high rate of inter-coder reliability, we decided to 
divide the remaining 70 articles equally between the three authors. During this last step of our detailed 
reading and coding, we decide to exclude a further four articles from our final sample (n=79). These 
articles were excluded because they only superficially referred to shortages and focused on other 
topics e.g. clinical research on doses of critical ingredients to be included in a vaccine. The list below 
presents the OSCM-oriented papers focusing on drug shortages, as a sample of the articles we coded.  
The full list of the 79 articles we coded and the accompanying master file including our coding of each 
article are available upon request.  
 
 
List of OSCM-oriented articles on drug shortages 
 
Azghandi, R., Griffin, J. and Jalali, M. S. (2018), “Minimization of drug shortages in pharmaceutical 
supply chains: A simulation-based analysis of drug recall patterns and inventory policies”, Complexity, 
doi.org/10.1155/2018/6348413. 
 
Chang, J., Lu, H. and Shi, J. (2019), “Stock out risk of production-inventory systems with compound 
Poisson demands, Omega, Vol. 83, pp. 181-198. 
 
Dai, T., Cho, S-H. and Zhang, F. (2016), “Contracting for on-time delivery in the US influenza vaccine 




Jia, J., and Zhao, H. (2017), “Mitigating the U.S. drug shortages with Pareto-improving contracts”, 
Production and Operations Management, Vol. 26 No. 8, pp.1463–1480. 
 
Kochan, C. G., Nowicki, D. R., Sauser, B., and Randall, W. S. (2018), “Impact of cloud-based information 
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of Production Economics, Vol. 195, pp. 168 185. 
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